circadian clock raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-17 and is reviewed periodically as new material appears.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
The role of the other BDNF receptor, p75, is less clear. While the TrkB receptor interacts with BDNF in a ligand-specific manner, all neurotrophins can interact with the p75 receptor. When the p75 receptor is activated, it leads to activation of NFkB receptor. Thus, neurotrophic signaling may trigger apoptosis rather than survival pathways in cells expressing the p75 receptor in the absence of Trk receptors. Recent studies have revealed a truncated isoform of the TrkB receptor (t-TrkB) may act as a dominant negative to the p75 neurotrophin receptor, inhibiting the activity of p75, and preventing BDNF-mediated cell death.
229Th has a nuclear isomer, 229mTh, with an excitation energy of 8.355733554021(8) eV. This is by far the lowest of all nuclear isomers. Because this energy lies between thorium's first and second ionization energies of 6.3 and 11.5 eV, the decay rate of 229mTh is sensitive to the electronic environment of the nucleus. In neutral 229mTh, the isomer decays by internal conversion to 229Th+ within a few microseconds. However, the isomeric energy is not enough to remove a second electron, so internal conversion is impossible in 229mTh+ ions; they are forced to decay radiatively with a half-life 8.4 orders of magnitude longer, in excess of 1000 seconds. Embedded in ionic crystals, ionization is not quite 100%, so a small amount of internal conversion occurs, leading to a recently measured lifetime of ≈600 s, which can be extrapolated to a lifetime for isolated ions of 1740±50 s. Any photon emitted by nuclear decay is called a gamma ray, but this "gamma ray" has a frequency of 2020407384335±2 kHz (wavelength 148.3821828827(15) nm), in te far ultraviolet. This means it is possible to build a laser operating at this frequency, giving the only known opportunity for direct laser excitation of a nuclear state. This could have applications like a nuclear clock of very high accuracy or as a qubit for quantum computing. These applications were for a long time impeded by imprecise measurements of the isomeric energy, as laser excitation's exquisite precision makes it difficult to use to search a wide frequency range.
Canagliflozin, sold under the brand name Invokana among others, is a medication used to treat type 2 diabetes. It is used together with exercise and diet. It is not recommended in type 1 diabetes. It is taken by mouth. Common side effects include vaginal yeast infections, nausea, constipation, and urinary tract infections. Serious side effects may include low blood sugar, Fournier's gangrene, leg amputation, kidney problems, high blood potassium, and low blood pressure. Diabetic ketoacidosis may occur despite nearly normal blood sugar levels. Use in pregnancy and breastfeeding is not recommended. Canagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor. It works by increasing the amount of glucose lost in the urine. Canagliflozin was approved for medical use in the United States, in the European Union, and in Australia in 2013. It is on the World Health Organization's List of Essential Medicines.
A total of thirteen Special Narcotics-Control Courts were supposed to be operating by mid-1989, with two in each of the districts of La Paz, Cochabamba, Santa Cruz, and Beni, and only one responsible for the five remaining departments. Their judges, adjunct prosecutors, and support staff were to receive higher salaries than other judicial officials. However, the Paz Zamora government reportedly planned to disband these courts.
Sources: en.wikipedia.org
Failure of safety-critical polymer components can cause serious accidents, such as fire in the case of cracked and degraded polymer fuel lines. Chlorine-induced cracking of acetal resin plumbing joints and polybutylene pipes has caused many serious floods in domestic properties, especially in the US in the 1990s. Traces of chlorine in the water supply attacked polymers present in the plumbing, a problem which occurs faster if any of the parts have been poorly extruded or injection molded. Attack of the acetal joint occurred because of faulty molding, leading to cracking along the threads of the fitting where there is stress concentration.
=== Atlas Copco (2014-present) === The Atlas Copco Group, a Swedish multinational industrial company, acquires Edwards Vacuum. Edwards purchased Brooks Automation's CTI-Cryogenics and Polycold branded cryopump operations based in Chelmsford and Monterrey for US$675 million in 2018. In 2019, Edwards marked its 100th anniversary. Its new North America Semiconductor Technology Centre in Hillsboro opened in the same year. Edwards joined MIT.nano as a founding member, following its completion in 2018. MIT.nano is a 214,000-square-foot laboratory dedicated to the characterisation and fabrication of nanoscale materials, structures, devices, and processes. In 2020, the company opened a new Service Technology Centre in Dublin. In 2022, Edwards invested in a new facility to manufacture products for the semiconductor industry in Arizona, USA. During the same year, Edwards acquired Ceres Technologies, Inc.. Ceres is a US-based manufacturer and designer of gas and vapour delivery equipment for the semiconductor industry. It also purchased HHV Pumps Pvt Ltd, a designer and manufacturer of vacuum pumps located in Bengalaru, India, for £10.9 million. Atlas Copco also agreed to purchase the assets of Chinese, liquid ring vacuum pump manufacturer Shandong Jinggong Pump Co Ltd, to join the Edwards vacuum pump business.
Lieutenant General Constand Viljoen, the chief of the South African Army, had told the task force commanders and his immediate superior General Johannes Geldenhuys that Cassinga was a PLAN "planning headquarters" which also functioned as the "principal medical centre for the treatment of seriously injured guerrillas, as well as the concentration point for guerrilla recruits being dispatched to training centres in Lubango and Luanda and to operational bases in east and west Cunene." The task force was made up of older Citizen Force reservists, many of whom had already served tours on the border, led by experienced professional officers. The task force of about 370 paratroops entered Cassinga, which was known as Objective Moscow to the SADF, in the wake of an intense aerial bombardment. From this point onward, there are two differing accounts of the Cassinga incident. While both concur that an airborne South African unit entered Cassinga on 4 May and that the paratroopers destroyed a large camp complex, they diverge on the characteristics of the site and the casualties inflicted. The SWAPO and Cuban narrative presented Cassinga as a refugee camp, and the South African government's narrative presented Cassinga as a guerrilla base. The first account claimed that Cassinga was housing a large population of civilians who had fled the escalating violence in northern South West Africa and were merely dependent on PLAN for their sustenance and protection.
Sources: en.wikipedia.org
The first of China's nuclear weapons tests took place in 1964, and its first hydrogen bomb test occurred in 1967 at Lop Nur. Tests continued until 1996, when the country signed the Comprehensive Nuclear-Test-Ban Treaty (CTBT), but did not ratify it. The number of nuclear warheads in China's arsenal remains a state secret. There are varying estimates of the size of China's arsenal. The Bulletin of the Atomic Scientists and Federation of American Scientists estimated in 2024 that China has a stockpile of approximately 438 nuclear warheads, while the United States Department of Defense put the estimate at more than 500 operational nuclear warheads, making it the third-largest in the world. China's policy has traditionally been one of no first use while maintaining a deterrent retaliatory force targeted for countervalue targets. According to a 2023 study by the National Defense University, China's nuclear doctrine has historically leaned toward maintaining a secure second-strike capability.
=== Predators === The species Hydra oligactis is preyed upon by the flatworm Microstomum lineare. Some Coleps sp. have also been observed to attack Hydra polyps in groups, with them attacking Hydras' tentacles first before consuming the entire polyps. Some other common predators include carnivorous or omnivorous fishes such as guppies, bettas, and gouramis.
=== G04BD Drugs for urinary frequency and incontinence === G04BD01 Emepronium G04BD02 Flavoxate G04BD03 Meladrazine G04BD04 Oxybutynin G04BD05 Terodiline G04BD06 Propiverine G04BD07 Tolterodine G04BD08 Solifenacin G04BD09 Trospium G04BD10 Darifenacin G04BD11 Fesoterodine G04BD12 Mirabegron G04BD13 Desfesoterodine G04BD14 Imidafenacin G04BD15 Vibegron
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.